Patents Assigned to Immuno Aktiengesellschaft
-
Publication number: 20050249815Abstract: There is disclosed a method of preparing a plasma-protein-containing medicament from citrated plasma or from a citrate-containing plasma fraction, the medicament being substantially free from undesired metals, which method comprises the following steps: exchanging the citrate and optionally citrate-bound metals in a plasma-protein-containing solution for a water-soluble mono- or dicarboxylate or for an organic mono- or dicarboxylic acid under non-precipitating conditions, recovering the plasma protein or the plasma proteins, and finishing the medicament.Type: ApplicationFiled: June 14, 2005Publication date: November 10, 2005Applicant: Immuno AktiengesellschaftInventors: Wolfgang Teschner, Yendra Linnau, Sonja Svatos, Herwig Igel
-
Patent number: 6103693Abstract: The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt.The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active.Further, the invention relates to a pharmaceutical preparation that contains rvWF, which is comprised of multimers with a high structural integrity.Type: GrantFiled: July 22, 1997Date of Patent: August 15, 2000Assignee: Immuno AktiengesellschaftInventors: Bernhard Fischer, Artur Mitterer, Friedrich Dorner, Hans-Peter Schwarz, Peter Turecek, Johann Eibl, Falko-Guenter Falkner, Uwe Schlokat, Wolfgang Mundt, Manfred Reiter, Renate Den-Bouwmeester
-
Patent number: 6100061Abstract: Disclosed are a stable recombinant cell clone which is stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.Type: GrantFiled: June 19, 1998Date of Patent: August 8, 2000Assignee: Immuno AktiengesellschaftInventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
-
Patent number: 6005077Abstract: The invention relates to the use of von Willebrand Factor (vWF) with a prolonged biological half-life for the production of a preparation for stabilization of blood coagulation Factor VIII (FVIII:C) in a mammal. Additionally, a pharmaceutical preparation is provided comprising a biologically active FVIII:C/vWF complex with improved pharmokinetic properties, said complex containing a vWF with a prolonged biological half-life.Type: GrantFiled: November 6, 1996Date of Patent: December 21, 1999Assignee: Immuno AktiengesellschaftInventors: Hans-Peter Schwarz, Peter Turecek, Johann Eibl
-
Patent number: 5962405Abstract: The invention relates to storage-stable fibrinogen preparations for preparing concentrated fibrinogen solution for use as a tissue adhesive or for preparing fibrinogen solutions for other uses, for example, for infusion purposes. The fibrinogen preparations are characterized in that(i) the lyophilized preparation comprises a substance improving the solubility of fibrinogen such that the reconstitution time is up to 15 minutes, preferably less than 7 minutes, when dissolving with water at room temperature to a solution with a fibrinogen concentration of at least 70 mg/ml and(ii) the ready-to-use tissue adhesive solution obtained from the preparation forms fibrin clots having physiological fibrin structure after mixing with a thrombin-CaCl.sub.2 solution.Type: GrantFiled: April 23, 1997Date of Patent: October 5, 1999Assignee: Immuno AktiengesellschaftInventor: Thomas Seelich
-
Patent number: 5892005Abstract: The invention provides high and low molecular weight fraction of von Willebrand Factor (vWF), which can be obtained by absorbing vWF to a heparin affinity support followed by eluting the vWF at differing salt concentrations.Type: GrantFiled: December 19, 1996Date of Patent: April 6, 1999Assignee: Immuno AktiengesellschaftInventors: Bernhard Fischer, Artur Mitterer, Friedrich Dorner
-
Patent number: 5883078Abstract: A stable tissue adhesive is described which comprises fibrinogen and an activator or pro-activator of prothrombin, wherein its content of prothrombin present in blood is less than 5 units/g fibrinogen. This tissue adhesive can be present as a liquid or dry preparation and can optionally be applied to a biologically degradable water-soluble support.Type: GrantFiled: June 10, 1996Date of Patent: March 16, 1999Assignee: Immuno AktiengesellschaftInventors: Thomas Seelich, Peter Turecek
-
Patent number: 5880265Abstract: The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt.The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active.Further, the invention relates to a pharmaceutical preparation that contains rvWF, which is comprised of multimers with a high structural integrity.Type: GrantFiled: July 22, 1997Date of Patent: March 9, 1999Assignee: Immuno AktiengesellschaftInventors: Bernhard Fischer, Artur Mitterer, Friedrich Dorner, Hans-Peter Schwarz, Peter Turecek, Johann Eibl, Falko-Guenter Falkner, Uwe Schlokat, Wolfgang Mundt, Manfred Reiter, Renate Den-Bouwmeester
-
Patent number: 5877152Abstract: The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt.The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant vWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active.Type: GrantFiled: July 22, 1997Date of Patent: March 2, 1999Assignee: Immuno AktiengesellschaftInventors: Bernhard Fischer, Artur Mitterer, Friedrich Dorner, Hans-Peter Schwarz, Peter Turecek, Johann Eibl, Falko-Guenter Falkner, Uwe Schlokat, Wolfgang Mundt, Manfred Reiter, Renate Den-Bouwmeester
-
Patent number: 5872099Abstract: The present invention relates to a method for separation of vWF into high molecular vWF and low molecular vWF which is characterized in that vWF is bound to an affinity support and is then eluted at different salt concentrations.Type: GrantFiled: December 19, 1996Date of Patent: February 16, 1999Assignee: Immuno AktiengesellschaftInventors: Bernhard Fischer, Arthur Mitterer, Friedrich Dorner
-
Patent number: 5869617Abstract: The invention provides high and low molecular weight fraction of von Willebrand Factor (vWF), which can be obtained by absorbing vWF to a heparin affinity support followed by eluting the vWF at differing salt concentrations The low molecular weight fraction is predominantly dimers and tetramers, and the high molecular weight fraction is predominantly larger multimers.Type: GrantFiled: October 4, 1995Date of Patent: February 9, 1999Assignee: Immuno AktiengesellschaftInventors: Bernhard Fischer, Artur Mitterer, Friedrich Dorner
-
Patent number: 5866122Abstract: There is disclosed a pharmaceutical preparation for treating blood coagulation disorders which comprises purified prothrombinase factors, in particular purified prothrombin and optionally purified factor Xa as active component.Type: GrantFiled: March 20, 1997Date of Patent: February 2, 1999Assignee: Immuno AktiengesellschaftInventors: Peter Turecek, Hans-Peter Schwarz, Johann Eibl
-
Patent number: 5864016Abstract: A blood product, exclusive of albumin, inactivated relative to infectious agents, the blood product conforming to a total virus reduction factor of at least 40, having a biological acitity of at least 50%, based on its activity prior to effecting inactivation of the infectious agents, the blood product being producible from conventional blood products and being virus-safe.Type: GrantFiled: July 28, 1994Date of Patent: January 26, 1999Assignee: Immuno AktiengesellschaftInventors: Johann Eibl, Friedrich Elsinger, Yendra Linnau, Gunther Wober
-
Patent number: 5858658Abstract: A method of quantitating genomic DNA in a sample is provided. The method comprises the steps of adding to the sample a given amount of at least one nucleic acid as an internal standard, wherein the standard nucleic acid differs from the genomic DNA to be quantified in at least one detectable characteristic; amplifying the genomic DNA and the internal standard nucleic acid by means of a nucleic acid amplification process employing primers complementary to repetitive genomic sequences; determining as a first amount the amount of amplified genomic DNA, and determining as a second amount the amount of amplified standard nucleic acid; and determining from the first and second amounts, as a third amount, the amount of genomic DNA originally contained in the sample. Kits for performing the method and products substantially free of foreign DNA as determined by the method also are provided.Type: GrantFiled: September 26, 1995Date of Patent: January 12, 1999Assignee: Immuno AktiengesellschaftInventors: Thomas Haemmerle, Falko-Guenter Falkner, Johann Kohl, Michele Himmelspach, Friedrich Dorner
-
Patent number: 5854403Abstract: The invention relates to a method for isolation of highly pure von Willebrand Factor in which recombinant von Willebrand Factor (rvWF) is chromatographically purified by anion exchange chromatography on an anion exchanger of the quaternary amino type in a buffer solution comprising buffer substances and optionally salt. The buffer solutions are preferably free of stabilizers, amino acids and other additives. According to this method, highly pure recombinant rvWF can be obtained, which is free from blood plasma proteins, especially free from Factor VIII, and is physiologically active. Further, the invention relates to a pharmaceutical preparation that contains rvWF, which comprises mulitimers with a high structural integrity.Type: GrantFiled: May 24, 1996Date of Patent: December 29, 1998Assignee: Immuno AktiengesellschaftInventors: Bernhard Fischer, Artur Mitterer, Friedrich Dorner, Hans-Peter Schwarz, Peter Turecek, Johann Eibl, Falko-Guenter Falkner, Uwe Schlokat, Wolfgang Mundt, Manfred Reiter, Renate Den-Bouwmeester
-
Patent number: 5833984Abstract: Inflammation can be treated or prevented altogether by administering a preparation comprising IgA. These preparations also can effect immunomodulation. Preferably, the preparation includes multimeric IgA and is essentially free of IgG in its various forms. Other compounds, such as antibiotics, antiphlogistic agents and antacids, also may be administered. Immunoglobulin A may also be used in vaccines to prevent inflammation. Additionally, an improved assay for evaluating anti-inflammatory activity is provided.Type: GrantFiled: December 23, 1996Date of Patent: November 10, 1998Assignee: Immuno AktiengesellschaftInventors: Martha Eibl, Hermann Wolf, Josef W. Mannhalter, Heinz Leibl, Yendra Linnau
-
Patent number: 5830467Abstract: A pharmaceutical preparation contains protein C and a thrombolytically active substance that does not activate protein C. This preparation prevents reocclusion usually occurring in the course of thrombolysis therapy.Type: GrantFiled: June 1, 1995Date of Patent: November 3, 1998Assignee: Immuno AktiengesellschaftInventors: Johann Eibl, Anton Philapitsch, Hans Peter Schwarz
-
Patent number: 5829634Abstract: A method and an apparatus for discharging a frozen blood product from a container, wherein, for automating purposes, the surface layer of the frozen blood product on the container wall is slightly thawed by heating from outside, whereby a liquid film is formed between the ice core and the container wall, and the container is opened to form a discharge opening on one side, whereupon the ice core is squeezed out of the container by aid of pressing elements, under application of pressure forces acting on the container and on the ice core, starting from the opposite side of the discharge opening.Type: GrantFiled: April 14, 1997Date of Patent: November 3, 1998Assignee: Immuno AktiengesellschaftInventors: Rudolf Gloger, Peter Neuper
-
Patent number: 5827818Abstract: The invention relates to a pharmaceutical agent which is suitable for subcutaneous injection of protein C, wherein it comprises protein C and a pharmaceutically acceptable carrier.Type: GrantFiled: March 20, 1996Date of Patent: October 27, 1998Assignee: Immuno AktiengesellschaftInventors: Johann Eibl, Hans-Peter Schwarz
-
Patent number: 5808000Abstract: A virus-safe monomeric human IgA is described which is essentially free of IgG. The IgA according to the invention is obtainable according to a process in which (a) an IgA-containing fraction is subjected to a purification such that a monomeric IgA which is essentially free of IgG is obtained and (b) the obtained product is subjected to a process for the inactivation of viruses.Type: GrantFiled: July 10, 1995Date of Patent: September 15, 1998Assignee: Immuno AktiengesellschaftInventors: Josef W. Mannhalter, Heinz Leibl, Martha Eibl, Regine Tomasits, Hermann Wolf